RLAYRelay Therapeutics Inc
−1,7% today · +182,9% over a year
2/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 18% of the instruments we score
Trend: among the best of its peers; Quality, Stability: among the weakest; priced higher than most peers. No dividend.
Ratios vs sector
Medians of Health care companies in the same region (stocks and REITs).
| Metric | RLAY | Sector median | vs median |
|---|---|---|---|
| P/E | — | 28,8 · n=114 | — |
| P/B | 4,2 | 3,0 · n=197 | 39% above |
| P/S | 361,2 | 3,8 · n=203 | 9.524% above |
| EV/EBIT | — | 24,1 · n=103 | — |
| Free-cash-flow yield | — | 2,7% · n=188 | — |
| Dividend yield | 0,00% | 0,00% · n=216 | — |
| Return on equity | −36,8% | 2,4% · n=194 | 1.629% below |
| Return on invested capital | −47,0% | 3,4% · n=177 | 1.484% below |
| Gross margin | — | 62,5% · n=152 | — |
| Net debt / EBITDA | — | 1,19 · n=108 | — |
Value factor: 13 of 100 within the peer group. Full score breakdown →
Sector peers
The largest companies of the same sector and region.
| Instrument | P/E | P/B | EV/EBIT | Free-cash-flow yield | Dividend yield | Smart Score |
|---|---|---|---|---|---|---|
| LLYEli Lilly & Co | 42,6 | 33,6 | — | 1,6% | 0,6% | 6/10 |
| JNJJohnson & Johnson | 29,1 | 7,2 | — | 3,6% | 2,1% | 8/10 |
| ABBVAbbVie | 79,9 | — | 33,5 | 3,6% | 3,0% | 5/10 |
| MRKMerck | 114,6 | 8,7 | — | 4,4% | 2,3% | 8/10 |
| UNHUnitedHealth | 25,1 | 3,4 | 18,6 | 6,7% | 2,3% | 9/10 |
| TMOThermo Fisher Scientific | 35,7 | 4,7 | 35,2 | 2,9% | 0,3% | 8/10 |
| AMGNAmgen | 26,3 | 19,7 | 24,0 | 4,4% | 2,3% | 6/10 |
| GILDGILEAD | — | 16,1 | — | 6,8% | 2,1% | 4/10 |
| ABTAbbott | 28,5 | 3,4 | 26,8 | 4,1% | 3,0% | 5/10 |
| PFEPfizer | 38,4 | 2,0 | — | 6,6% | 5,9% | 1/10 |
Fiscal-year history
From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.
Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 jun 2026 · filed 06 aug 2026
Hier opzeggen · EU-consumenten: 14 dagen bedenktijd bij aankoop.